Six months ago start-up firm Epiphany Biosciences in-licensed a compound for varicella zoster virus. With the closing of a $36 million Series A round, the company now is poised to advance that product through Phase IIb trials, as well as continue work on a blood-screening product for herpesvirus-8. (BioWorld Today)